Author： Gardian Gabriella Yang Lichuan Cleren Carine Calingasan Noel Y. Klivenyi Peter Beal M. Flint
Publisher： Humana Press, Inc
ISSN： 1535-1084
Source： NeuroMolecular Medicine, Vol.5, Iss.3, 2004-06, pp. : 235-242
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
There is increasing evidence that administration of histone deacetylase (HDAC) inhibitors can exert neuroprotective effects by a variety of mechanisms. Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects. These include several antioxidant enzymes, chaperones, and genes involved in cell survival. We examined whether administration of phenylbutyrate could exert significant neuroprotective effects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which has been used to model Parkinson's disease. Administration of phenylbutyrate significantly attenuated MPTP-induced depletion of striatal dopamine and loss of tyrosine hydroxylase-positive neurons in the substantia nigra. These findings provide further evidence that administration of phenylbutyrate may be a useful approach for the treatment of neurodegenerative diseases.
Related content
Access to resources
Recommend
By Azadmehr Abbas Oghyanous Keyvan Hajiaghaee Reza Amirghofran Zahra Azadbakht Mohammad
Cellular and Molecular Neurobiology, Vol. 33, Iss. 8, 2013-11 ,pp. :